Comparison between Gland Pharma IPO and IRFC IPO.
Gland Pharma IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while IRFC IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Gland Pharma IPO is up to ₹6,479.55 Cr whereas the issue size of the IRFC IPO is up to ₹4,633.38 Cr. The final issue price of Gland Pharma IPO is ₹1,500.00 per share and of IRFC IPO is ₹26.00 per share.
| Gland Pharma IPO | IRFC IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹10 per share |
| Issue Price (Lower) | ₹1,490.00 per share | ₹25.00 per share |
| Issue Price (Upper) | ₹1,500.00 per share | ₹26.00 per share |
| Issue Price (Final) | ₹1,500.00 per share | ₹26.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 10 shares | 575 shares |
| Fresh Issue Size | 83,33,333 shares | 1,18,80,46,000 shares |
| Fresh Issue Size (Amount) | up to ₹1,250.00 Cr | up to ₹3,088.92 Cr |
| OFS Issue Size | 3,48,63,635 shares | 59,40,23,000 shares |
| OFS Issue Size (Amount) | up to ₹5,229.55 Cr | up to ₹1,544.46 Cr |
| Issue Size Total | 4,31,96,968 shares | 1,78,20,69,000 shares |
| Issue Size Total (Amount) | up to ₹6,479.55 Cr | up to ₹4,633.38 Cr |
Gland Pharma IPO opens on Nov 09, 2020, while IRFC IPO opens on Jan 18, 2021. The closing date of Gland Pharma IPO and IRFC IPO is Nov 11, 2020, and Jan 20, 2021, respectively.
| Gland Pharma IPO | IRFC IPO | |
|---|---|---|
| Anchor Bid Date | Nov 06, 2020 | Jan 15, 2021 |
| Issue Open | Nov 09, 2020 | Jan 18, 2021 |
| Issue Close | Nov 11, 2020 | Jan 20, 2021 |
| Basis Of Allotment (Tentative) | Nov 17, 2020 | Jan 25, 2021 |
| Initiation of Refunds (Tentative) | Nov 18, 2020 | Jan 27, 2021 |
| Credit of Share (Tentative) | Nov 19, 2020 | Jan 28, 2021 |
| Listing date (Tentative) | Nov 20, 2020 | Jan 29, 2021 |
| Anchor Lockin End date 1 | Dec 17, 2020 | Feb 24, 2021 |
| Anchor Lockin End date 2 | Feb 15, 2021 | Apr 25, 2021 |
Gland Pharma IPO P/E ratio is , as compared to IRFC IPO P/E ratio of .
| Gland Pharma IPO | IRFC IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 74 | 100 | ||||
| Promoter Shareholding (Post-Issue) | 58 | 86 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹24492.42 Cr. | ₹33978.12 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Gland Pharma IPO Retail Individual Investors (RII) are offered 1,51,18,939 shares while in IRFC IPO retail investors are offered 1,51,18,939 shares. Qualified Institutional Buyers (QIB) are offered 86,39,394 shares in Gland Pharma IPO and 35,63,75,339 shares in IRFC IPO.
| Gland Pharma IPO | IRFC IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,29,59,089 shares | 53,45,63,007 shares |
| Market Maker Reservation | ||
| QIB | 86,39,394 shares | 35,63,75,339 shares |
| NII | 64,79,546 shares | 26,72,81,504 shares |
| RII | 1,51,18,939 shares | 62,36,56,843 shares |
| Employee | 1,92,307 shares | |
| Others | ||
| Total | 4,31,96,968 shares | 1,78,20,69,000 shares |
Gland Pharma IPO subscribed 2.06x in total, whereas IRFC IPO subscribed 3.49x.
| Gland Pharma IPO | IRFC IPO | |
|---|---|---|
| QIB (times) | 6.40x | 3.78x |
| NII (times) | 0.51x | 2.67x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 0.24x | 3.66x |
| Employee (times) | 43.76x | |
| Other (times) | ||
| Total (times) | 2.06x | 3.49x |
